相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer
Jiaqiong Wang et al.
CLINICAL NUCLEAR MEDICINE (2020)
Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride
A. M. Garcia Vicente et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Keiichiro Mori et al.
CLINICAL GENITOURINARY CANCER (2019)
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
Thorsten D. Poeppel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Nobuaki Matsubara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al.
EUROPEAN UROLOGY (2018)
Therapy assessment of bone metastatic disease in the era of 223radium
Elba Etchebehere et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database
D. Keizman et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)
E. David Crawford et al.
UROLOGY (2017)
Management of metastatic castration-resistant prostate cancer: A focus on radium-223 Opinions and suggestions from an expert multidisciplinary panel
Sergio Baldari et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
Dipenkumar Modi et al.
CLINICAL GENITOURINARY CANCER (2016)
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer
Hojjat Ahmadzadehfar et al.
CLINICAL NUCLEAR MEDICINE (2016)
Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)
Daniel Keizman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.
Aurelius Gabriel Omlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S. Gillessen et al.
ANNALS OF ONCOLOGY (2015)
Clinical utility of 18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study
Sonia Rodado-Marina et al.
BJU INTERNATIONAL (2015)
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
Megan A. McNamara et al.
BMC CANCER (2015)
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer
Hossein Jadvar et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
Kalevi Kairemo et al.
DIAGNOSTICS (2015)
Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer
Kyle S. Miyazaki et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group
F. E. Lecouvet et al.
EUROPEAN JOURNAL OF CANCER (2014)
Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
John M. Fitzpatrick et al.
EUROPEAN JOURNAL OF CANCER (2014)
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
Ethan Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
E. David Crawford et al.
UROLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2013)
Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?
Michael J. Morris et al.
SEMINARS IN ONCOLOGY (2013)
Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy
Chiara Fuccio et al.
EUROPEAN JOURNAL OF RADIOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
Charles J. Ryan et al.
CLINICAL CANCER RESEARCH (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy
Chiara Fuccio et al.
ANNALS OF NUCLEAR MEDICINE (2010)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer
P. F. Mulders et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2009)
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT:: a comparative study
Mohsen Beheshti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
EAU guidelines on prostate cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
